Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
AIDS ; 13(12): 1503-9, 1999 Aug 20.
Artigo em Inglês | MEDLINE | ID: mdl-10465074

RESUMO

OBJECTIVE: To establish the feasibility of using ultrasound-guided lymph node needle aspiration as a means to obtain lymphoid tissue cells for the determination of a series of immunologic and virologic measures in HIV-infected patients. DESIGN: First, a comparison of the characteristics of cell populations obtained by simultaneous needle aspiration and standard excisional biopsy in six patients. Second, use of lymph node needle aspiration to assess longitudinally T-cell subset changes in patients initiating highly effective antiretroviral treatment. METHODS: T-cell subsets (CD4 and CD8) and percentage Ki67+ cycling T cells were measured in lymph node cell populations harvested by ultrasound-guided aspiration or standard biopsy by flow cytometry. Cellular RNA content was assessed by a modification of the Roche Amplicor HIV-1 Monitor test. RESULTS: CD4 and CD8 T-cell percentage and HIV RNA cell content of lymph node cell suspensions obtained from the simultaneous performance of ultrasound-guided needle aspiration and excisional biopsy in the same patients were correlated (n = 6). Among the 87 aspiration sessions reported here, mononuclear cell suspensions were obtained in 100% of the sessions, in numbers ranging between 4x10(4) to 6.7x10(6) cells (median: 7x10(5)). This limited number of cells did not allow to perform all type of analyses in all patients. By prioritizing the cells for the determination of T-cell subsets and proliferation rate, this approach was instrumental for demonstrating the normalization of the T-cell subset ratio and the kinetic of normalization of proliferating rates of CD4 and CD8 T cells, as well as the decrease in HIV-1 viral load in the lymph node following HAART initiation. CONCLUSION: Ultrasound-guided aspiration appears to be a non-invasive and ad libitum, safe and repeatable procedure for the longitudinal monitoring of changes in lymph nodes.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Biópsia por Agulha , Infecções por HIV/tratamento farmacológico , Infecções por HIV/imunologia , Linfonodos/patologia , Linfócitos T CD4-Positivos/imunologia , Linfócitos T CD8-Positivos/imunologia , Carbamatos , Didesoxinucleosídeos/uso terapêutico , Quimioterapia Combinada , Citometria de Fluxo , Furanos , Infecções por HIV/virologia , Inibidores da Protease de HIV/uso terapêutico , HIV-1/genética , Humanos , Estudos Longitudinais , Linfonodos/diagnóstico por imagem , Linfonodos/imunologia , Ativação Linfocitária , RNA Viral/análise , Inibidores da Transcriptase Reversa/uso terapêutico , Sulfonamidas/uso terapêutico , Ultrassonografia
2.
AIDS ; 15(17): 2287-92, 2001 Nov 23.
Artigo em Inglês | MEDLINE | ID: mdl-11698702

RESUMO

OBJECTIVE: To assess the impact of primary HIV infection (PHI) on the spread of HIV and the temporal trends in transmission of HIV drug resistance between 1996 and 1999 in Switzerland. METHODS: Sequencing of the genes for reverse transcriptase (RT) and protease was performed for 197 individuals with documented PHI. Phylogenetic analyses were confronted with epidemiological data. RESULTS: Significant clustering was demonstrated for 29% of the RT sequences. All these cases occurred closely together in place and time; contact tracing demonstrated transmission at the time of PHI in 30% of them. Genotypic drug resistance was detected in 8.6% of PHI individuals in 1996, 14.6% in 1997, 8.8% in 1998 and 5.0% in 1999. Drug-resistant variants were identified in 11.3% of individuals infected by homosexual contacts, 6.1% by heterosexual contacts, 13% of intravenous drug users and more frequently in men (10.4%) than women (2.6%). Potential factors involved in the recent decrease of transmission of drug-resistant variants include increase of HIV non-B subtypes from 23% in 1996 to 35% in 1999 (only one non-B subtype had resistance mutations) and a steady increase of patients with undetectable viraemia as documented in Swiss HIV Cohort Study (10% in 1996 vs 53% in 1999). CONCLUSIONS: Phylogenetic and epidemiological analyses underline the impact of PHI in the spread of HIV. Moreover, this study indicates that drug resistance transmission may have decreased recently in Switzerland through the increased frequency of infection with HIV non-B subtypes and the steady increase of patients with undetectable viraemia.


Assuntos
Farmacorresistência Viral , Infecções por HIV/transmissão , HIV-1/efeitos dos fármacos , Doença Aguda , Adolescente , Adulto , Idoso , Farmacorresistência Viral/genética , Feminino , Variação Genética , Infecções por HIV/epidemiologia , Infecções por HIV/imunologia , Infecções por HIV/virologia , Protease de HIV/genética , Transcriptase Reversa do HIV/genética , HIV-1/classificação , HIV-1/enzimologia , HIV-1/genética , Humanos , Masculino , Pessoa de Meia-Idade , Filogenia , Suíça/epidemiologia
3.
Int J Epidemiol ; 23(2): 359-64, 1994 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-8082963

RESUMO

This Italian study, based on the National Household Health Survey (NHHS), the Registry of the Blind and the Welfare lists of the Ministry of the Interior, was designed to estimate the prevalence of blindness and hypovision in Italy and describe its geographical distribution. In addition, a national sample of 29 763 Registry members was studied to describe causes of blindness. The prevalence from NHHS data was 4.3 per 1000 in 1983 and 4.5 in 1986-1987 (3.2 in the North, 4.6 in the Centre, 6.5 in the South). Welfare recipients were 112,783 in 1988, a prevalence of 2.0 per 1,000, but were fewer in Northern than in Southern regions (range 0.7-4.8). The Registry of the Blind had 80,918 members in 1984 (prevalence 1.4 per 1,000) and 106,000 in 1989 (prevalence 1.9): < 1 per 1,000 in the North and > 3 in the South. The most frequent causes of blindness among Registry members were retinal diseases (33%) and cataract (23%). The causes of preventable blindness were more frequently reported in Southern than in Northern Italy.


Assuntos
Cegueira/epidemiologia , Baixa Visão/epidemiologia , Adolescente , Adulto , Idoso , Cegueira/etiologia , Causalidade , Criança , Pré-Escolar , Estudos Transversais , Oftalmopatias/complicações , Oftalmopatias/epidemiologia , Feminino , Inquéritos Epidemiológicos , Humanos , Incidência , Lactente , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Sistema de Registros , Baixa Visão/etiologia
4.
Ther Drug Monit ; 23(5): 553-5, 2001 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11591903

RESUMO

Abacavir and amprenavir, a nucleoside reverse transcription inhibitor and a protease inhibitor, respectively, are new drugs used for the treatment of HIV. Methadone blood concentrations were measured in five addict patients receiving methadone maintenance therapy before and after introduction of abacavir plus amprenavir. The administration of these two drugs for a median period of 14 days resulted in a significant reduction (P = 0.043) of methadone concentration, with a median decrease to 35% of the original concentration (range 28-87%). Two patients reported on several occasions nausea in the morning before the intake of the daily methadone dose, which is compatible with withdrawal reaction to opioids. Because amprenavir is a cytochrome P4503A4 substrate and is involved in the metabolism of methadone, reduction of methadone concentrations could be explained by an induction of cytochrome P4503A4.


Assuntos
Analgésicos Opioides/sangue , Didesoxinucleosídeos/farmacologia , Inibidores da Protease de HIV/farmacologia , Metadona/sangue , Inibidores da Transcriptase Reversa/farmacologia , Sulfonamidas/farmacologia , Síndrome da Imunodeficiência Adquirida/complicações , Síndrome da Imunodeficiência Adquirida/tratamento farmacológico , Carbamatos , Interações Medicamentosas , Quimioterapia Combinada , Furanos , HIV-1/efeitos dos fármacos , Humanos , Transtornos Relacionados ao Uso de Substâncias/complicações
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA